Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
The New England Journal of Medicine
|
November 16, 1995
Doxorubicin-induced cardiotoxicity
L Paz-Ares, N Dobbs, C Twelves
British Journal of Cancer
|
June 6, 2000
Serum vascular endothelial growth factor load and interleukin-6 in cancer patients
K J O'Byrne, N Dobbs, A L Harris
Virginia Dental Journal
|
December 1, 1982
Obturation technique for large root canal systems
J B Holcomb, R N Dobbs, P T Umstott
Lancet (London, England)
|
May 8, 1999
Vascular endothelial growth factor platelet counts, and prognosis in renal cancer
K J O'Byrne, N Dobbs, D Propper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2001
Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy
A L Harris, P Reusch, B Barleon, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 25, 2025
Incorporating Complementary Therapies Into Diabetes Care
Julia E Blanchette, Forrest Paquin, Brandi N Dobbs, et al.
The Yale Journal of Biology and Medicine
|
November 1, 1989
Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience
P W Heald, M I Perez, I Christensen, et al.
British Journal of Cancer
|
May 1, 1992
Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters
P J Johnson, N Dobbs, C Kalayci, et al.
Journal of Hepatology
|
July 1, 1991
Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol
P J Johnson, C Kalayci, N Dobbs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2003
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies
J P Braybrooke, E Boven, N P Bates, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
The New England Journal of Medicine
|
November 16, 1995
Doxorubicin-induced cardiotoxicity
L Paz-Ares, N Dobbs, C Twelves
British Journal of Cancer
|
June 6, 2000
Serum vascular endothelial growth factor load and interleukin-6 in cancer patients
K J O'Byrne, N Dobbs, A L Harris
Virginia Dental Journal
|
December 1, 1982
Obturation technique for large root canal systems
J B Holcomb, R N Dobbs, P T Umstott
Lancet (London, England)
|
May 8, 1999
Vascular endothelial growth factor platelet counts, and prognosis in renal cancer
K J O'Byrne, N Dobbs, D Propper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2001
Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy
A L Harris, P Reusch, B Barleon, et al.
The Journal of Clinical Endocrinology and Metabolism
|
February 25, 2025
Incorporating Complementary Therapies Into Diabetes Care
Julia E Blanchette, Forrest Paquin, Brandi N Dobbs, et al.
The Yale Journal of Biology and Medicine
|
November 1, 1989
Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience
P W Heald, M I Perez, I Christensen, et al.
British Journal of Cancer
|
May 1, 1992
Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters
P J Johnson, N Dobbs, C Kalayci, et al.
Journal of Hepatology
|
July 1, 1991
Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol
P J Johnson, C Kalayci, N Dobbs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2003
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies
J P Braybrooke, E Boven, N P Bates, et al.
Page
of 2